308 related articles for article (PubMed ID: 23508772)
21. [Psoriasis updates].
Boulinguez S
Ann Dermatol Venereol; 2010 May; 137(5 Suppl 1):1-4. PubMed ID: 20510173
[No Abstract] [Full Text] [Related]
22. Switching to adalimumab in patients with moderate to severe psoriasis who have failed on etanercept: a retrospective case cohort study.
Woolf RT; Smith CH; Robertson K; Barker JN
Br J Dermatol; 2010 Oct; 163(4):889-92. PubMed ID: 20854408
[No Abstract] [Full Text] [Related]
23. [Long-term psoriasis treatment].
Jullien D; Battistella M
Ann Dermatol Venereol; 2011 Feb; 138(2 Suppl 1):H15-8. PubMed ID: 21396519
[No Abstract] [Full Text] [Related]
24. The status of biologic therapies in the treatment of moderate to severe psoriasis.
Menter A
Cutis; 2009 Oct; 84(4 Suppl):14-24. PubMed ID: 19916298
[TBL] [Abstract][Full Text] [Related]
25. Experience with biologics for psoriasis in daily practice: switching is worth a try.
Lecluse LL; de Groot M; Bos JD; Spuls PI
Br J Dermatol; 2009 Oct; 161(4):948-51. PubMed ID: 19663876
[No Abstract] [Full Text] [Related]
26. Pediatric psoriasis: updates in biologic therapies.
Sukhatme SV; Gottlieb AB
Dermatol Ther; 2009; 22(1):34-9. PubMed ID: 19222515
[TBL] [Abstract][Full Text] [Related]
27. Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up.
Dewedar AM; Shalaby MA; Al-Homaid S; Mahfouz AM; Shams OA; Fathy A
Int J Rheum Dis; 2012 Jun; 15(3):330-5. PubMed ID: 22709496
[TBL] [Abstract][Full Text] [Related]
28. [European and British recommendations on the role of biologic interventions in moderate to severe psoriasis].
Bachelez H; Battistella M
Ann Dermatol Venereol; 2011 Apr; 138(2 Suppl 2):H14-7. PubMed ID: 21703457
[No Abstract] [Full Text] [Related]
29. Efficacy and safety of ustekinumab and etanercept for the treatment of psoriasis.
Uhlenhake EE; Feldman SR
Expert Opin Biol Ther; 2010 Jul; 10(7):1105-12. PubMed ID: 20446825
[TBL] [Abstract][Full Text] [Related]
30. A scientific debate: key clinical questions in the management of psoriasis.
Stingl G
J Eur Acad Dermatol Venereol; 2012 Aug; 26 Suppl 5():1. PubMed ID: 22758910
[No Abstract] [Full Text] [Related]
31. Three-year registry data on biological treatment for psoriasis: the influence of patient characteristics on treatment outcome.
Driessen RJ; Boezeman JB; van de Kerkhof PC; de Jong EM
Br J Dermatol; 2009 Mar; 160(3):670-5. PubMed ID: 19210502
[TBL] [Abstract][Full Text] [Related]
32. Pustular psoriasis following treatment of rheumatoid arthritis with TNF-alpha inhibitors.
Egnatios G; Warthan MM; Pariser R; Hood AF
J Drugs Dermatol; 2008 Oct; 7(10):975-7. PubMed ID: 19112764
[No Abstract] [Full Text] [Related]
33. Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris.
Gniadecki R; Kragballe K; Dam TN; Skov L
Br J Dermatol; 2011 May; 164(5):1091-6. PubMed ID: 21219290
[TBL] [Abstract][Full Text] [Related]
34. Consecutive use of different biological therapies in the treatment of psoriasis.
Costanzo A; Papoutsaki M; Mazzotta A; Chimenti S
Br J Dermatol; 2007 Aug; 157(2):394. PubMed ID: 17553044
[No Abstract] [Full Text] [Related]
35. [Tolerance of biological agents in children].
Bader-Meunier B
Arch Pediatr; 2010 Jun; 17(6):962-3. PubMed ID: 20654981
[No Abstract] [Full Text] [Related]
36. Safety of anti-TNFα agents in the treatment of psoriasis and psoriatic arthritis.
Girolomoni G; Altomare G; Ayala F; Berardesca E; Calzavara-Pinton P; Chimenti S; Peserico A; Puglisi Guerra A; Vena GA
Immunopharmacol Immunotoxicol; 2012 Aug; 34(4):548-60. PubMed ID: 22296031
[TBL] [Abstract][Full Text] [Related]
37. Is there a benefit from using a subsequent anti-TNF α medication in psoriasis patients who failed their first or second anti-TNF α agent?
Alsharqi A; Parslew R; Dever B; Arslanian V
Australas J Dermatol; 2012 May; 53(2):e45-7. PubMed ID: 22571585
[No Abstract] [Full Text] [Related]
38. Detection and management of latent tuberculosis infections before biologic therapy for psoriasis.
Amerio P; Amoruso G; Bardazzi F; Campanati A; Cassano N; Conti A; Gisondi P; Guarneri C; Mazzotta A; Piaserico S; Prestinari F; Prignano F; Zane C; de Simone C
J Dermatolog Treat; 2013 Aug; 24(4):305-11. PubMed ID: 22208431
[TBL] [Abstract][Full Text] [Related]
39. Adalimumab vs. etanercept in psoriasis.
Downs AM
Clin Exp Dermatol; 2007 Sep; 32(5):593. PubMed ID: 17692064
[No Abstract] [Full Text] [Related]
40. Treatment of nail psoriasis with tumor necrosis factor-alpha blocker agents: an open-label, unblinded, comparative study.
Ozmen I; Erbil AH; Koc E; Tunca M
J Dermatol; 2013 Sep; 40(9):755-6. PubMed ID: 23834032
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
